Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine

Krystle A. Lang; Jian Yan; Ruxandra Draghia-Akli; Amir Khan; David B. Weiner

doi:10.1016/j.vaccine.2008.07.052

Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine

Krystle A. Lang, Jian Yan, Ruxandra Draghia-Akli, Amir Khan, David B. Weiner

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Hepatitis C virus (HCV) represents a major health burden with more than 170 million individuals currently infected worldwide, equaling roughly 3% of the world's population. HCV preferentially infects hepatocytes and is able to persist in up to 70% of infected individuals. It is estimated that up to 30% of chronically infected individuals will go on to develop progressive liver disease as a result of HCV infection, making the virus the leading cause of liver transplantation in the world. Currently there is no vaccine for HCV. In this study, we have taken a multi-step approach to develop a novel genotype 1a/1b consensus HCV NS3/NS4A DNA vaccine able to induce strong cellular immunity. We show that this construct is able to induce strong anti-NS3/NS4A T cell responses in C57BL/6 mice, as well as, in Rhesus macaques. Our data suggest that DNA vaccines encoding HCV proteins NS3/NS4A merit further study in the context of future prophylactic and therapeutic HCV T cell based vaccines.

Original language	English
Pages (from-to)	6225-6231
Number of pages	7
Journal	Vaccine
Volume	26
Issue number	49
DOIs	https://doi.org/10.1016/j.vaccine.2008.07.052
State	Published - Nov 18 2008

Bibliographical note

Funding Information:
This manuscript was supported in part by funding from the NIH to DBW and from VGX Pharmaceuticals, Inc. The laboratory notes possible commercial conflicts associated with this work, which may include; Wyeth, VGX, BMS, Virxsys, Ichor, Merck, Althea, & Aldeveron.

Keywords

Consensus
DNA vaccine
HCV
NS3
NS4A

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2008.07.052

Cite this

@article{eb969b631a1341de9dc27de512bea7ca,

title = "Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine",

abstract = "Hepatitis C virus (HCV) represents a major health burden with more than 170 million individuals currently infected worldwide, equaling roughly 3% of the world's population. HCV preferentially infects hepatocytes and is able to persist in up to 70% of infected individuals. It is estimated that up to 30% of chronically infected individuals will go on to develop progressive liver disease as a result of HCV infection, making the virus the leading cause of liver transplantation in the world. Currently there is no vaccine for HCV. In this study, we have taken a multi-step approach to develop a novel genotype 1a/1b consensus HCV NS3/NS4A DNA vaccine able to induce strong cellular immunity. We show that this construct is able to induce strong anti-NS3/NS4A T cell responses in C57BL/6 mice, as well as, in Rhesus macaques. Our data suggest that DNA vaccines encoding HCV proteins NS3/NS4A merit further study in the context of future prophylactic and therapeutic HCV T cell based vaccines.",

keywords = "Consensus, DNA vaccine, HCV, NS3, NS4A",

author = "Lang, {Krystle A.} and Jian Yan and Ruxandra Draghia-Akli and Amir Khan and Weiner, {David B.}",

note = "Funding Information: This manuscript was supported in part by funding from the NIH to DBW and from VGX Pharmaceuticals, Inc. The laboratory notes possible commercial conflicts associated with this work, which may include; Wyeth, VGX, BMS, Virxsys, Ichor, Merck, Althea, & Aldeveron.",

year = "2008",

month = nov,

day = "18",

doi = "10.1016/j.vaccine.2008.07.052",

language = "English",

volume = "26",

pages = "6225--6231",

number = "49",

}

TY - JOUR

T1 - Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine

AU - Lang, Krystle A.

AU - Yan, Jian

AU - Draghia-Akli, Ruxandra

AU - Khan, Amir

AU - Weiner, David B.

N1 - Funding Information: This manuscript was supported in part by funding from the NIH to DBW and from VGX Pharmaceuticals, Inc. The laboratory notes possible commercial conflicts associated with this work, which may include; Wyeth, VGX, BMS, Virxsys, Ichor, Merck, Althea, & Aldeveron.

PY - 2008/11/18

Y1 - 2008/11/18

N2 - Hepatitis C virus (HCV) represents a major health burden with more than 170 million individuals currently infected worldwide, equaling roughly 3% of the world's population. HCV preferentially infects hepatocytes and is able to persist in up to 70% of infected individuals. It is estimated that up to 30% of chronically infected individuals will go on to develop progressive liver disease as a result of HCV infection, making the virus the leading cause of liver transplantation in the world. Currently there is no vaccine for HCV. In this study, we have taken a multi-step approach to develop a novel genotype 1a/1b consensus HCV NS3/NS4A DNA vaccine able to induce strong cellular immunity. We show that this construct is able to induce strong anti-NS3/NS4A T cell responses in C57BL/6 mice, as well as, in Rhesus macaques. Our data suggest that DNA vaccines encoding HCV proteins NS3/NS4A merit further study in the context of future prophylactic and therapeutic HCV T cell based vaccines.

AB - Hepatitis C virus (HCV) represents a major health burden with more than 170 million individuals currently infected worldwide, equaling roughly 3% of the world's population. HCV preferentially infects hepatocytes and is able to persist in up to 70% of infected individuals. It is estimated that up to 30% of chronically infected individuals will go on to develop progressive liver disease as a result of HCV infection, making the virus the leading cause of liver transplantation in the world. Currently there is no vaccine for HCV. In this study, we have taken a multi-step approach to develop a novel genotype 1a/1b consensus HCV NS3/NS4A DNA vaccine able to induce strong cellular immunity. We show that this construct is able to induce strong anti-NS3/NS4A T cell responses in C57BL/6 mice, as well as, in Rhesus macaques. Our data suggest that DNA vaccines encoding HCV proteins NS3/NS4A merit further study in the context of future prophylactic and therapeutic HCV T cell based vaccines.

KW - Consensus

KW - DNA vaccine

KW - HCV

KW - NS3

KW - NS4A

UR - http://www.scopus.com/inward/record.url?scp=55249115746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249115746&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.07.052

DO - 10.1016/j.vaccine.2008.07.052

M3 - Article

C2 - 18692108

AN - SCOPUS:55249115746

SN - 0264-410X

VL - 26

SP - 6225

EP - 6231

JO - Vaccine

JF - Vaccine

IS - 49

ER -

Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this